These findings suggest that SAL ameliorates liver inflammation and oxidative stress caused by cholestasis through the activation of the PI3K/AKT/GSK-3β signaling pathway and inhibits the activation of HSC and liver fibrosis, suggesting that SAL is a potential therapeutic agent for cholestatic liver injury. The gene discussed is GSK3B; the disease is Hepatic fibrosis.